NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis $3.66 -0.06 (-1.61%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Kiora Pharmaceuticals alerts: Email Address About Kiora Pharmaceuticals Stock (NASDAQ:KPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kiora Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.63▼$3.8350-Day Range$3.10▼$4.7052-Week Range$3.00▼$8.98Volume12,712 shsAverage Volume83,292 shsMarket Capitalization$10.68 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingStrong Buy Company OverviewKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Read More… Forget Trump and Kamala (Ad)Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.Download my Dividend Calendar here Kiora Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 71st PercentileKiora Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 222nd out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingKiora Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Kiora Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $1.17 to ($2.23) per share.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kiora Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently decreased by 34.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.22% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently decreased by 34.78%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for KPRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,625.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiora Pharmaceuticals' insider trading history. Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KPRX Stock News HeadlinesKiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Aron Shapiro Buys 3,000 SharesSeptember 12, 2024 | insidertrades.comBuy Rating on Kiora Pharmaceuticals Amid Promising Clinical Trials and Strong FinancialsAugust 23, 2024 | markets.businessinsider.comMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.September 20, 2024 | Unstoppable Prosperity (Ad)Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 ProgressAugust 10, 2024 | markets.businessinsider.comKiora Pharmaceuticals Inc (7EY0.MU)August 8, 2024 | nz.finance.yahoo.comBuy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial DataMay 20, 2024 | markets.businessinsider.comKiora Pharmaceuticals, Inc. (KPRX)May 19, 2024 | finance.yahoo.comBuy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical TrialsMay 11, 2024 | markets.businessinsider.comSee More Headlines KPRX Stock Analysis - Frequently Asked Questions How have KPRX shares performed this year? Kiora Pharmaceuticals' stock was trading at $4.7016 at the beginning of 2024. Since then, KPRX shares have decreased by 22.2% and is now trading at $3.66. View the best growth stocks for 2024 here. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) issued its quarterly earnings results on Friday, August, 9th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.42. The firm earned $0.02 million during the quarter. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals shares reverse split on the morning of Tuesday, June 11th 2024. The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. Who are Kiora Pharmaceuticals' major shareholders? Kiora Pharmaceuticals' top institutional shareholders include AIGH Capital Management LLC (8.76%), Rosalind Advisors Inc. (8.75%), Nantahala Capital Management LLC (7.24%) and Stonepine Capital Management LLC (6.86%). Insiders that own company stock include Brian M Strem, Eric Joseph Daniels, Erin Parsons, Melissa Tosca, Aron Shapiro and Lisa Walters-Hoffert. View institutional ownership trends. How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/09/2024Today9/20/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPRX CUSIPN/A CIK1372514 Webeyegatepharma.com Phone(781) 788-9043FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+169.0%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,510,000.00 Net MarginsN/A Pretax Margin20.54% Return on Equity15.57% Return on Assets11.34% Debt Debt-to-Equity RatioN/A Current Ratio19.22 Quick Ratio19.22 Sales & Book Value Annual Sales$16 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book0.52Miscellaneous Outstanding Shares2,917,000Free Float2,890,000Market Cap$10.85 million OptionableNot Optionable Beta-0.26 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:KPRX) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.